BR0015195A - Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma condição associada com a transmissão reduzida de nicotina para o tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para o tratamento ou profilaxia de doenças ou condições humanas - Google Patents

Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma condição associada com a transmissão reduzida de nicotina para o tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para o tratamento ou profilaxia de doenças ou condições humanas

Info

Publication number
BR0015195A
BR0015195A BR0015195-5A BR0015195A BR0015195A BR 0015195 A BR0015195 A BR 0015195A BR 0015195 A BR0015195 A BR 0015195A BR 0015195 A BR0015195 A BR 0015195A
Authority
BR
Brazil
Prior art keywords
compound
alkyl
treatment
prophylaxis
hydrogen
Prior art date
Application number
BR0015195-5A
Other languages
English (en)
Inventor
David Gurley
Thomas Lanthorn
John Macor
James Rosamond
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0015195A publication Critical patent/BR0015195A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, E, MéTODOS PARA O TRATAMENTO DE UMA CONDIçãO ASSOCIADA COM A TRANSMISSãO REDUZIDA DE NICOTINA, PARA O TRATAMENTO OU PROFILAXIA DE DISTúRBIOS PSICóTICOS OU DISTúRBIOS DE DETERIORAçãO INTELECTUAL E PARA O TRATAMENTO OU PROFILAXIA DE DOENçAS OU CONDIçõES HUMANAS". Um composto de Fórmula (I), em que R^ 1^ e R^ 3^ representam, independentemente, hidrogênio ou C~ 1~-C~ 4~ alquila; R^ 2^ representa hidrogênio, C~ 1~-C~ 4~ alquila ou CH~ 2~CN; R^ 4^ representa hidrogênio, C~ 1~-C~ 4~-alquila, C~ 2~-C~ 4~ alquenila, C~ 2~-C~ 4~ alquinila, CH~ 2~C(W)=CH~ 2~, (CH~ 2~)nAr, CH~ 2~CH=CHAr, CH~ 2~COPh, CH~ 2~CONHAr, C(U)NH(CH~ 2~)mAr ou (CH~ 2~)dY(CH~ 2~)eAr; U representa O, ou S; W representa halogênio; X e Y representam independentemente O, S ou NR^ 5^; R^ 5^ representa hidrogênio, C~ 1~-C~ 4~ alquila, C~ 2~-C~ 4~ alquenila; ou juntos R^ 3^ e R^ 5^ formam um anel; n e m são, independentemente, 0-4; d é 1-3; e é 0-1; Ar representa fenila, naftila ou anel heterocíclico de 5 ou 6-membros, contendo zero a quatro nitrogênios, zero a um enxofre e zero a um oxigênio; Ar é opcionalmente substituído com um ou mais substituintes selecionados de: hidrogênio, halogênio, C~ 1~-C~ 4~ alquila, C~ 2~-C~ 4~ alquinila CN, NO~ 2~, CF~ 3~, OR^ 6^, NR^ 7^R^ 8^, COOR^ 9^; R^ 6^, R^ 7^ e R^ 8^ são, independentemente, hidrogênio, C~ 1~-C~ 4~ alquila, arila, heteroarila, C(O)R^ 10^, C(O)NHR^ 11^, SO~ 2~R^ 12^, ou R^ 7^ e R^ 8^ juntos podem ser (CH~ 2~)jQ(CH~ 2~) k, em que: Q é O, S, NR^ 13^ ou uma ligação; j é 2-4; k é 0-2; R^ 9^, R^ 10^, R^ 11^, R^ 12^ e R^ 13^ são, independentemente, hidrogênio, C~ 1~-C~ 4~ alquila, arila ou heteroarila; ou um seu enanciómero, e seus sais farmaceuticamente aceitáveis, processos para prepará-los, composições farmacêuticas contendo-os e seu uso em terapia, especialmente para tratamento de condições associadas com reduções de transmissão nicotínica. Os compostos da invenção aumentam a eficácia dos agonistas nos receptores nicotínicos.
BR0015195-5A 1999-11-03 2000-11-01 Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma condição associada com a transmissão reduzida de nicotina para o tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para o tratamento ou profilaxia de doenças ou condições humanas BR0015195A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9903997A SE9903997D0 (sv) 1999-11-03 1999-11-03 New compounds
PCT/SE2000/002148 WO2001032619A1 (en) 1999-11-03 2000-11-01 Positive modulators of nicotinic receptor agonists

Publications (1)

Publication Number Publication Date
BR0015195A true BR0015195A (pt) 2002-06-18

Family

ID=20417607

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015195-5A BR0015195A (pt) 1999-11-03 2000-11-01 Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma condição associada com a transmissão reduzida de nicotina para o tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para o tratamento ou profilaxia de doenças ou condições humanas

Country Status (16)

Country Link
US (1) US6750242B1 (pt)
EP (1) EP1230216A1 (pt)
JP (1) JP2003513071A (pt)
KR (1) KR20020063176A (pt)
CN (1) CN1239482C (pt)
AU (1) AU783507B2 (pt)
BR (1) BR0015195A (pt)
CA (1) CA2387745A1 (pt)
CO (1) CO5251458A1 (pt)
IL (1) IL149098A0 (pt)
MX (1) MXPA02004232A (pt)
NO (1) NO323076B1 (pt)
NZ (2) NZ518450A (pt)
SE (1) SE9903997D0 (pt)
WO (1) WO2001032619A1 (pt)
ZA (1) ZA200203171B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903998D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
DE10234424A1 (de) * 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
CA2495248A1 (en) 2002-08-30 2004-03-11 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegenerative diseases
AU2003276919B2 (en) 2002-09-25 2013-05-16 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
CN103724343A (zh) 2004-03-25 2014-04-16 记忆药物公司 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途
US7375219B2 (en) 2005-04-13 2008-05-20 Neuraxon, Inc. Substituted indole compounds having NOS inhibitory activity
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
TW200808780A (en) * 2006-04-13 2008-02-16 Neuraxon Inc 1,5 and 3,6- substituted indole compounds having NOS inhibitory activity
US20090131503A1 (en) * 2007-11-16 2009-05-21 Annedi Subhash C 3,5 - substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
BRPI0820632A2 (pt) 2007-11-16 2015-06-16 Neuraxon Inc Compostos de indol e métodos para tratamento de dor visceral
WO2009064505A1 (en) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
WO2009100294A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Amide derivatives as positive allosteric modulators and methods of use thereof
EP2279183B1 (en) 2008-04-17 2012-08-08 Proximagen Limited Indoles as modulators of nicoticic acetylcholine receptor subtype alpha-7
SG175084A1 (en) * 2009-04-16 2011-11-28 Proximagen Ltd Indole derivative modulators of the alpha 7 nachr
AR081402A1 (es) 2010-05-17 2012-08-29 Envivo Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida monohidrato
TW201245185A (en) 2011-04-01 2012-11-16 Lundbeck & Co As H New positive allosteric modulators of nicotinic acetylcholine receptor
AR086791A1 (es) 2011-07-01 2014-01-22 Lundbeck & Co As H Moduladores alostericos positivos del receptor de acetilcolina nicotinico
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
KR102242658B1 (ko) * 2018-08-29 2021-04-21 숙명여자대학교산학협력단 치환된 인돌 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 PPARα, PPARγ 및 PPARδ 관련 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2787551A (en) * 1954-02-24 1957-04-02 Eastman Kodak Co Compositions stabilized with hydroxyindole
BE758766A (fr) * 1969-11-17 1971-05-10 Ici Ltd Nouveaux derives de la morpholine et de la
US4704390A (en) * 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
KR930702334A (ko) * 1990-09-13 1993-09-08 데이비드 로버트 5 하이드록시트립타민 수용체 길항제로서의 인돌우레아
KR0184911B1 (ko) * 1991-11-25 1999-05-01 알렌 제이. 스피겔 인돌유도체
WO1993018026A1 (en) * 1992-03-04 1993-09-16 Beecham Group Plc Indole ureas as 5-ht1c receptor antogonists
US5504101A (en) * 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
FR2722686B1 (fr) * 1994-07-22 1996-08-30 Oreal Set, procede, dispositif et composition de teinture des fibres keratiniques
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems

Also Published As

Publication number Publication date
ZA200203171B (en) 2003-09-23
KR20020063176A (ko) 2002-08-01
CN1387512A (zh) 2002-12-25
CO5251458A1 (es) 2003-02-28
NZ518450A (en) 2004-04-30
NO20022009D0 (no) 2002-04-26
WO2001032619A1 (en) 2001-05-10
CA2387745A1 (en) 2001-05-10
EP1230216A1 (en) 2002-08-14
MXPA02004232A (es) 2002-10-17
JP2003513071A (ja) 2003-04-08
NO323076B1 (no) 2006-12-27
NO20022009L (no) 2002-07-02
AU783507B2 (en) 2005-11-03
NZ530161A (en) 2005-08-26
AU1426401A (en) 2001-05-14
CN1239482C (zh) 2006-02-01
SE9903997D0 (sv) 1999-11-03
US6750242B1 (en) 2004-06-15
IL149098A0 (en) 2002-11-10

Similar Documents

Publication Publication Date Title
BR0015195A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma condição associada com a transmissão reduzida de nicotina para o tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para o tratamento ou profilaxia de doenças ou condições humanas
BR0015193A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma condição associada com trasmissão reduzida de nicotina, para tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para tratamento ou profilaxia de doenças ou condições humanas
YU49443B (sh) Derivati benzimidazola, postupci za njihovo pripremanje i primena tih derivata u medicinskoj terapiji, naročito za lečenje ili sprečavanje virusnih infekcija
MY132872A (en) Benzimidazole derivatives.
DK1487829T3 (da) Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte
DE60010076D1 (de) Chinolinderivate als antibakterielle mittel
AR013184A1 (es) Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
DK0958296T3 (da) Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
BR9812046A (pt) Compostos, processos para a preperação do composto e para tratar um paciente humano ou animal, composição farmacêutica, e, uso de um composto
HUP0001062A2 (hu) NAALADáz gátló hatású foszfinsavszármazékokat tartalmazó gyógyászati készítmények
BR0108456A (pt) Composto, uso de um composto, métodos de tratamento ou de profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e de doenças humanas, e ,processo para preparação de um composto
HUP0400710A2 (hu) Tioéter helyettesítővel helyettesített imidazokinolinszármazékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
BR9912729A (pt) Derivado de amida, processo para prepará-lo, e, uso do mesmo
DE69930926D1 (de) Benzolsulfonamid-derivate und ihre anwendung als arzneimittel
ATE273958T1 (de) Heterocyclische verbindungen als h+-atpasen
BR0311541A (pt) indol, azaindol e 4-aquenil piperidina amidas heterocìclicas relacionadas
FI870421A (fi) Analogiamenetelmä alkueläintenvastaisesti vaikuttavien 5,6-dihydro-2-(substituoitu fenyyli)-1,2,4-triatsiini-3,5(2H,4H)-dionijohdannaisten valmistamiseksi
HUP0002272A2 (hu) Piperazinszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
BR0317680A (pt) Composto, composição farmacêutica, uso de um composto, ou de um sal farmaceuticamente aceitável do mesmo, método de tratamento de um ser humano, e, processo para a preparação de um composto
BR9807950A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto
NO905620L (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater.
DE69828197D1 (de) Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
PT982305E (pt) Novos derivados do indano-1-ol proceso para a sua preparacao e as composicoes farmaceuticas que os contem
TR200200485T2 (tr) Yeni A-500359 türevleri.
ATE247903T1 (de) Fungizide zusammensetzung enthaltend ein n- benzoyl-n'-phenyl-harnstoff derivat

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.